Cutis-Biotech, a pharmaceutical firm, filed a suit in the civil court claiming it was a prior user of the brandname Covishield, and sought to restrain SII from using the name.
In a tweet, Serum Institute of India CEO Adar Poonawalla said, "Our partnership for a Covid-19 vaccine with Novavax has also published excellent efficacy results.”
Covaxin is contraindicated for people who use blood thinners, while Covishield asks recipients to inform physician. But doctors say there’s no rationale.
SII official says Covishield vaccines are safe and the manufacturing site is also unaffected after fire breaks out at the Serum Institute's Manjari facility, which is under construction.
Dhaka’s announcement comes a day after a meeting between the Modi govt and vaccine makers Bharat Biotech and SII to discuss India’s export plan for Covid vaccines.
Analysts say supply to government amid low distribution, marketing and R&D costs could aid profits. Bharat Biotech vaccine is priced at Rs 206 per dose while SII’s is at Rs 200.
Covishield will reach Brazil next week. Modi govt had earlier this month authorised a deal between Brazilian govt & Serum Institute to supply the vaccine at a ‘special rate’.
Govt firm will buy vaccines from Serum Institute of India & Bharat Biotech and supply them to Nepal, Bangladesh, Sri Lanka, Afghanistan, Seychelles and Mauritius.
The industry forecasts exports are set to grow 16% in 2025-26, boosted by surplus domestic production and a drive to push into 26 underserved global markets with strong potential.
Indigenisation level will progressively increase up to 60 percent with key sub-assemblies, electronics and mechanical parts being manufactured locally.
It is a brilliant, reasonably priced, and mostly homemade aircraft with a stellar safety record; only two crashes in 24 years since its first flight. But its crash is a moment of introspection.
Playing GOD will cost lives.